Multi-target peptide agonists represent the next frontier in peptide therapeutics, demonstrating superior efficacy in metabolic disorders compared to selective agonists. By activating multiple receptors simultaneously, these peptides provide complementary benefits that enhance therapeutic outcomes.
The most advanced multi-target agonists are in the GLP-1 family. Tirzepatide is a dual GLP-1/GIP agonist that has shown superior efficacy compared to selective GLP-1 agonists[reference:122]. Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors, with early clinical data suggesting even greater weight loss than existing therapies. These multi-target approaches are expanding the therapeutic possibilities for metabolic diseases.
The rationale for multi-target agonism is based on the complementary effects of different receptor pathways. GLP-1 agonism promotes insulin secretion and satiety. GIP agonism enhances insulin secretion and may have additional metabolic benefits. Glucagon agonism increases energy expenditure. By combining these effects, multi-target agonists can achieve greater efficacy than any single pathway alone.
Beyond metabolic diseases, multi-target peptide agonists are being investigated for other conditions. Peptides that activate multiple receptors in the same pathway may provide enhanced efficacy for cancer, inflammation, and neurological disorders. The approach is also being explored for antimicrobial peptides, where multi-target activity may reduce the likelihood of resistance.
The development of multi-target peptide agonists requires careful optimization to achieve balanced activity at multiple receptors. This optimization involves systematic modification of the peptide sequence, with each modification affecting activity at each receptor. At PeptideHub, we support the development of multi-target peptide agonists with custom synthesis and modification capabilities, enabling the optimization of these promising therapeutic candidates.